KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Accumulated Expenses: 2010-2025

Historic Accumulated Expenses for Emergent BioSolutions (EBS) over the last 16 years, with Sep 2025 value amounting to $36.6 million.

  • Emergent BioSolutions' Accumulated Expenses fell 42.18% to $36.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $36.6 million, marking a year-over-year decrease of 42.18%. This contributed to the annual value of $56.1 million for FY2024, which is 24.29% down from last year.
  • Emergent BioSolutions' Accumulated Expenses amounted to $36.6 million in Q3 2025, which was up 16.19% from $31.5 million recorded in Q2 2025.
  • In the past 5 years, Emergent BioSolutions' Accumulated Expenses registered a high of $88.7 million during Q4 2021, and its lowest value of $24.7 million during Q1 2025.
  • For the 3-year period, Emergent BioSolutions' Accumulated Expenses averaged around $54.9 million, with its median value being $56.8 million (2023).
  • Its Accumulated Expenses has fluctuated over the past 5 years, first climbed by 17.72% in 2022, then crashed by 52.77% in 2025.
  • Quarterly analysis of 5 years shows Emergent BioSolutions' Accumulated Expenses stood at $88.7 million in 2021, then declined by 1.58% to $87.3 million in 2022, then dropped by 15.12% to $74.1 million in 2023, then fell by 24.29% to $56.1 million in 2024, then crashed by 42.18% to $36.6 million in 2025.
  • Its Accumulated Expenses was $36.6 million in Q3 2025, compared to $31.5 million in Q2 2025 and $24.7 million in Q1 2025.